Business
AcuCort Secures New Order for Zeqmelit® - Continued Growth Across the Nordics
AcuCort Secures New Order for Zeqmelit® - Continued Growth Across the
About this update from Acucort Ab
AcuCort has received a new order for Zeqmelit® from its Nordic distribution partner, Unimedic Pharma . The order covers the Nordic market. Zeqmelit® was launched in Sweden , Norway , and Finland in September 2024 , followed by Denmark in the summer of 2025. The new order from Unimedic Pharma , AcuCort's Nordic distribution partner, is for the Nordic market. "The launch of Zeqmelit® is developing in line with expectations for a newly introduced pharmaceutical, which is very encouraging," says AcuCort's CEO, Jonas Jönmark. The order is valued at EUR 112,000 and is expected to have a positive impact on AcuCort's financial performance during the second quarter 2026. For further information: Jonas Jönmark, CEO, AcuCort AB Phone: 070 365 5400 E-mail: [email protected] About AcuCort AB (publ) AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden , Denmark , Norway , and Finland . AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market . Visit www.acucort.se for more information. https://news.cision.com/acucort-ab/r/acucort-secures-new-order-for-zeqmelit----continued-growth-across-the-nordics,c4278297 https://mb.cision.com/Main/15601/4278297/3829313.pdf (c) 2025 Cision. All rights reserved., source Press Releases - English